- Department of Health, Public Health England, and Administration of Radioactive Substances Advisory Committee
- Part of:
- Medical radiation: uses, dose measurements and safety advice
- 17 April 2014
- Last updated:
- 22 February 2017, see all updates
Guidance on certification and best use of radiopharmaceuticals and sealed radioactive sources in diagnosis, treatment or research.
Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and use of sealed Radioactive Sources
Ref: PHE publications gateway number: 2016613 PDF, 963KB, 84 pages
This file may not be suitable for users of assistive technology. Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email email@example.com. Please tell us what format you need. It will help us if you say what assistive technology you use.
This guidance to good clinical practice for nuclear medicine in the UK is the advice of the Administration of Radioactive Substances Advisory Committee (ARSAC).
The guide includes advice on ARSAC certificates to help health professionals fill in ARSAC application forms.
January 2017 edition
There have been a number of changes since the revision last year, these include:
- details of transfers of certificates
- revision of thyroid blocking guidance
- inclusion of additional PET radiopharmaceuticals in Appendix I
- amendment to the DRL for serial 43a3xiv
- addition of serial 43w70 Tc99m HYNIC-Ty3-octreotide
- changes to functional groups for sentinel lymph node biopsy serials for breast and melanoma
- a revised summary of the legislation most relevant to nuclear medicine practice
Published: 17 April 2014
Updated: 22 February 2017
- Uploaded the 2017 edition of guidance.
- January 2016 update to guidance.
- First published.